Clinical trials: Sensory Function
Dry Eye Disease, Dry Eye Sensation
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the…
- Conditions
- Dry Eye Disease, Dry Eye Sensation, Ocular Surface Disease
- Trial name
- NCT06375343
- Testing
- PRO-240, Optive®
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Tinnitus
The Treatment of Tinnitus With Transcutaneous Non-invasive Vagus Nerve Stimulation
The t-VNS STv3 device is a non-invasive, transcutaneous neurostimulator for influencing the afferent branches of the nervus vagus around the human ear.
- Trial name
- NCT01176734
- Testing
- tVNS-Device
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- cerbomed GmbH
Deafness, Hearing Loss
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
The rationale behind this post-market clinical follow-up investigation is to collect data regarding the usability and clinical performance of the Baha Attract System in subjects with hearing impairment that are candidates for…
- Conditions
- Deafness, Hearing Loss, Hearing Loss, Conductive
- Trial name
- NCT02022085
- Testing
- Baha Attract System
- Where
- 6 sites in United States, Netherlands and 2 more
- Volunteers
- 54 people
- Sponsor
- Cochlear Bone Anchored Solutions
Fibromyalgia
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia.
- Trial name
- NCT07637162
- Testing
- AXS-14 (esreboxetine)
- Where
- 35 sites in United States
- Volunteers
- 300 people
- Sponsor
- Axsome Therapeutics, Inc.
Retinitis Pigmentosa (RP), Usher Syndrome Type 2
Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
The purpose of this Phase 2 Open-label study is to evaluate the long-term safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in participants with Retinitis Pigmentosa due to mutations in exon 13…
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- CAPELLA (NCT07796646)
- Testing
- No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen
- Volunteers
- 81 people
- Sponsor
- Laboratoires Thea
Hearing Loss, Sensorineural, Hearing Loss
Speech Intelligibility in Quiet and Noise for New vs. Legacy Hearing Aids
This clinical investigation is designed to compare audiological performance (i.e., measurements of sound quality and speech understanding) between Starkey's new receiver-in-canal device and a commercially available legacy…
- Trial name
- NCT05101083
- Testing
- New Receiver-in-Canal Device, Legacy Receiver-in-Canal Device
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Starkey Laboratories, Inc
Hearing Loss
A Comparative Clinical Investigation of Two Hearing Instrument Digital Signal Processing
The purpose of this study is to show that the performance of the new digital signal processing system is better than the system used in the currently CE marked devices.
- Trial name
- NCT04374851
- Testing
- Polaris miniRITE BTE, Viron miniRiTE BTE
- Where
- Switzerland
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Bernafon AG
Neuropathic Pain, Diabetes
Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
The hypothesis of this Phase 2 study is that at least 1 dose regimen of DS-1971a will demonstrate clinical superiority to placebo in managing pain associated with DPNP, and will be generally well tolerated.
- Trial name
- NCT02673866
- Testing
- DS-1971a, pregabalin
- Sponsor
- Daiichi Sankyo
Hearing Loss
Evaluation of New Feedback Canceller for Carina™ Implant
The purpose of this study is to evaluate audio quality benefit for the patient implanted with a Cochlear or Otologics Carina implant with the new firmware (feedback canceller algorithm) whatever the patient environment is and to…
- Trial name
- NCT02309541
- Testing
- feedback canceller algorithm (Firmware)
- Where
- 3 sites in France
- Volunteers
- 12 people
- Sponsor
- Cochlear
Leber Congenital Amaurosis 10, Blindness
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
- Trial name
- HYPERION (NCT06891443)
- Testing
- sepofarsen
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 32 people
- Sponsor
- Laboratoires Thea
Renal Fanconi Syndrome, Photophobia
Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Cystinosis disease from the blood
- Conditions
- Renal Fanconi Syndrome, Photophobia, Hypophosphatemia
- Trial name
- BioCystinosis (NCT02837523)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Age-related Cataract, Vision Loss
Long-term Safety & Performance of REVISYON SDS100 in Mild to Moderate Cataract: Extension Study (EB-CE-02)
A non-interventional, extension study on the long-term maintenance of safety and performance of the REVISYON SDS 100 medical device in subjects with mild-to-moderate cataract.
- Conditions
- Age-related Cataract, Vision Loss, Cataract, Mild Cataract
- Trial name
- EB-CE-02 (NCT07246915)
- Where
- 6 sites in Romania
- Volunteers
- 47 people
- Sponsor
- Edinburgh Biosciences Ltd
Hearing Loss, Idiopathic Sudden Sensorineural
Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment
The primary objective of the trial is the confirmation of the efficacy of AM-111 in the recovery of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL).
- Trial name
- ASSENT (NCT02809118)
- Testing
- AM-111 0.4 mg/ml, AM-111 0.8 mg/ml
- Where
- 51 sites in United States, Canada and 1 more
- Volunteers
- 56 people
- Sponsor
- Auris Medical, Inc.
Hearing Impaired (Partially)
Optimization of Perceived Sound Quality for Music Listening in Hearing Aid Users With Hearing Loss.
This study aims to optimize music listening quality for 66 hearing aid users (33 musicians and 33 non-musician music enthusiasts) by developing a dedicated "Music Program" based on individual frequency preference profiles.
- Trial name
- OPTIMMUSIC (NCT07677748)
- Testing
- Musical listening quality preference test
- Volunteers
- 66 people
- Sponsor
- Institut Pasteur
Amblyopia
Luminopia One Amblyopia Vision Improvement Study
The objective of the study is to demonstrate the safety and efficacy of Luminopia One in amblyopia patients with amblyopia associated with anisometropia and/or with mild strabismus.
- Trial name
- NCT03608150
- Testing
- Luminopia One, Refractive Correction
- Where
- 22 sites in United States
- Volunteers
- 117 people
- Sponsor
- Luminopia
Hearing Loss
Assessment of Novel Sound Changing Principles in Hearing Instruments to Determine Their Application - 2018_12
A methodical evaluation of novel sound changing principles in CE-labelled Sonova brand hearing instruments (e.g. Phonak hearing instruments) is intended to be conducted on hearing impaired participants.
- Trial name
- NCT03554577
- Testing
- Hearing Aid without NR, Hearing Aid with NR_A, Hearing Aid with NR_B
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- Sonova AG
Hearing Loss, Sensorineural
Quality Control of CE-Certified Phonak Hearing Aids - 2018_07
Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner.
- Trial name
- NCT03555084
- Testing
- Extension of Virto B-Titanium, Virto B-Titanium
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Sonova AG
Pulsatile Tinnitus, Venous Sinus Stenosis
BosSTENT ImpLant to trEat debilitatiNg Pulse-synchronous Tinnitus
This study is evaluating the safety and clinical performance of the BosSTENT, a new stent designed specifically for treating pulse-synchronous tinnitus due to venous sinus stenosis.
- Trial name
- B-SILENT (NCT07070089)
- Testing
- BosSTENT implantation
- Where
- 6 sites in Canada, France
- Volunteers
- 90 people
- Sponsor
- Sonorous NV, Inc
Hearing Loss, Sensorineural
Standard Post Market Clinical Follow-up (PMCF) Study WSA 2026
The purpose of the study is to follow-up on a released low-risk device as part of standard PMCF activities.
- Trial name
- NCT07667140
- Testing
- In-the-Ear Hearing Aid, Own hearing aid
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- WSAUD A/S
Diabetic Macular Edema, Diabetic Retinopathy
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME).
- Trial name
- NCT05607810
- Testing
- ADVM-022
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Adverum Biotechnologies, Inc.